Identification | More | [Name]
Olmesartan | [CAS]
144689-24-7 | [Synonyms]
OLMESARTAN 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid Olmesartan 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2’-(1H-tetazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid CS 088 Olmesartan Acid RNH 6270 | [EINECS(EC#)]
646-413-5 | [Molecular Formula]
C24H26N6O3 | [MDL Number]
MFCD00914967 | [Molecular Weight]
446.5 | [MOL File]
144689-24-7.mol |
Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
186-188°C | [Boiling point ]
738.3±70.0 °C(Predicted) | [density ]
1.33 | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
powder | [pka]
2.39±0.50(Predicted) | [color ]
white to beige | [Usage]
An labelled angiotensin II receptor antagonist. Used as an anti-hypertensive | [Stability:]
Hygroscopic | [CAS DataBase Reference]
144689-24-7(CAS DataBase Reference) |
Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
An angiotensin II (AT1) receptor antagonist | [Uses]
An angiotensin II receptor antagonist. Used as an anti-hypertensive | [Uses]
An labelled angiotensin II receptor antagonist. Used as an anti-hypertensive | [Uses]
Angiotensin II inhibitor, antihypertensive | [Definition]
ChEBI: Olmesartan is a biphenylyltetrazole. It has a role as an antihypertensive agent and an angiotensin receptor antagonist. | [General Description]
Olmesartan medoxomil, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate (Benicar, Olmetec) uses the tetrazolering system as its acidic system, which participates inreceptor binding.When administered to a patient, the drugis rapidly and completely bioactivated by ester hydrolysis ofthe medoxomil during absorption from the gastrointestinaltract. Once the prodrug is converted to the active form, virtuallyno further metabolism occurs. In September 2007, theFood and Drug Administration (FDA) approved its use as acombination product with the calcium channel blocker amlodipinefor the management of hypertension. This combinationproduct is sold under the tradename of Azor. | [Biochem/physiol Actions]
Olmesartan possesses anti-inflammatory and anti-oxidative stress properties. It protects neuronal cells against oligomerized amyloid β (Aβ)-induced cellular senescence. | [storage]
Store at -20°C |
|
|